| Identification | Back Directory | [Name]
PSMA-617 | [CAS]
1702967-37-0 | [Synonyms]
PSMA-617
Vipivotide tetraxetan
L-Lysine, N2-[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]-N6-[3-(2-naphthalenyl)-N-[[trans-4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]methyl]cyclohexyl]carbonyl]-L-alanyl]- | [Molecular Formula]
C49H71N9O16 | [MDL Number]
MFCD31715458 | [MOL File]
1702967-37-0.mol | [Molecular Weight]
1042.14 |
| Chemical Properties | Back Directory | [Boiling point ]
1371.9±65.0 °C(Predicted) | [density ]
1.322±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Water:150.0(Max Conc. mg/mL);100.13(Max Conc. mM)
DMSO:125.0(Max Conc. mg/mL);83.43(Max Conc. mM) | [form ]
Solid | [pka]
1.83±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
JBHPLHATEXGMQR-LFWIOBPJSA-N | [SMILES]
C(O)(=O)[C@H](CCCCNC(=O)[C@H](CC1=CC=C2C(=C1)C=CC=C2)NC([C@@H]1CC[C@@H](CNC(CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)=O)CC1)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O |
| Hazard Information | Back Directory | [Uses]
PSMA-617 has been used in prostate cancer research, and is a promising prostate-specific membrane antigen-targeted theranostic agent. | [in vivo]
Organ distribution with 68Ga-labeled Vipivotide tetraxetan (PSMA-617) after 1 h (n=3) reveals a high specific uptake in LNCaP tumors and in the kidneys. The high uptake in the kidneys is nearly completely blocked by coinjection of 2 mg of 2-PMPA per kilogram. Other organs such as the liver, lung, and spleen show rather low uptake and no blocking effect, with the exception of the spleen. Tumor-to-background ratios are 7.8 (tumor to blood) and 17.1 (tumor to muscle) at 1 h after injection. As compared with the 68Ga-labeled version, the organ distribution with 177Lu-labeled Vipivotide tetraxetan (PSMA-617) (n=3) show a similar uptake in the LNCaP tumors and in the kidneys. The liver uptake is found to be statistically different. Tumor-to-background ratios determined 1 h after injection show slightly higher values (tumor to blood, 22.1; tumor to muscle, 25.6) than previous organ distribution with 68Ga-labeled Vipivotide tetraxetan (PSMA-617)[1]. | [IC 50]
Traditional Cytotoxic Agents | [storage]
Store at -20°C |
|
|